Trevi Therapeutics, Inc. (TRVI) – What Are Brokerages Saying About This Stock?

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $27.08.

Several analysts have recently commented on TRVI shares. B. Riley Financial raised their price objective on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Cantor Fitzgerald upped their target price on shares of Trevi Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Wall Street Zen cut Trevi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Oppenheimer reissued an “outperform” rating on shares of Trevi Therapeutics in a report on Friday, September 25th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Trevi Therapeutics in a research report on Wednesday, October 7th.

Trevi Therapeutics Stock Down 4.9%

TRVI stock opened at $12.29 on Wednesday. Trevi Therapeutics has a twelve month low of $9.28 and a twelve month high of $20.22. The stock has a market cap of $1.75 billion, a P/E ratio of -36.15 and a beta of 0.98. The business’s 50-day moving average price is $16.12 and its 200-day moving average price is $15.62.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, equities research analysts expect that Trevi Therapeutics will post -0.48 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Michael Heffernan sold 39,473 shares of Trevi Therapeutics stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total transaction of $595,647.57. Following the sale, the director owned 6,351 shares of the company’s stock, valued at approximately $95,836.59. This trade represents a 86.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 15.39% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Trevi Therapeutics in the second quarter worth about $208,041,000. Artia Global Partners LP purchased a new stake in shares of Trevi Therapeutics in the second quarter worth about $41,232,000. First Light Asset Management LLC bought a new position in Trevi Therapeutics during the second quarter valued at approximately $39,113,000. Bank of America Corp DE bought a new position in Trevi Therapeutics during the second quarter valued at approximately $28,588,000. Finally, Assenagon Asset Management S.A. bought a new position in Trevi Therapeutics during the second quarter valued at approximately $28,447,000. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for conditions involving chronic cough and other debilitating symptoms for which available treatment options are limited. The company’s lead product candidate is Haduvio, an extended-release formulation of nalbuphine, an opioid receptor modulator being investigated as a potential treatment for chronic cough.

Trevi is evaluating Haduvio for chronic cough associated with idiopathic pulmonary fibrosis (IPF), a progressive lung disease, as well as refractory chronic cough, which persists despite treatment of underlying conditions.